Actualizaciones regulatorias
Novedades regulatorias de FDA, EMA, TGA y organismos globales
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
FDA Approves ANDA203834 for Acyclovir Oral Tablets
The FDA has approved ANDA203834 for prescription oral acyclovir tablets (400 mg and 800 mg) manufactured by Camber Pharmaceuticals and sponsored by Hetero Labs.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
FDA Approves ANDA203048 for Clindamycin Phosphate Injection by Rising
The FDA granted approval for Rising’s clindamycin phosphate injection products (6, 12, and 18 mg/mL) under application ANDA203048.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
ICCA Releases J.06.01 & J.06.02 Alerts: Auto-Charting May Cause Fluid-Balance Errors
ICCA's J.06.01 and J.06.02 releases warn that auto‑charting of infusion data can produce incorrect intake, output and net body balance values for units using automatic charting settings.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
KPA Holds 352nd Day Relay Protest Demanding Resolution of Han Yak Sa Issues
The Korean Pharmacists Association staged its 352nd day relay protest in front of Cheong Wa Dae, urging swift government and parliamentary action on longstanding Han Yak Sa concerns.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
FDA Approves Jubilant Itraconazole 100 mg Capsule (ANDA203445)
FDA approved labeling for Jubilant Generics' oral itraconazole 100 mg capsule (ANDA203445); the product is listed as discontinued.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
Korea Serb... TipsoBoc (Ivosidenib) Begins Price Negotiation for IDH1‑Mutant Cholangiocarcinoma Reimbursement
TipsoBoc (ivosidenib) from Korea Serb... has entered health‑insurance price negotiations for IDH1‑mutant locally advanced or metastatic cholangiocarcinoma after passing the benefits evaluation committee in July.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
FDA Approves Zydus Pharms Indomethacin Extended‑Release Capsule (ANDA202711)
FDA has approved ANDA202711 for Zydus Pharms' prescription indomethacin 75 mg extended‑release oral capsule, with labeling supplements filed in 2017, 2019, 2021 and 2024.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
PRAMIPEXOLE DIHYDROCHLORIDE Extended‑Release Tablets Approved (ANDA202353)
FDA approved multiple oral extended‑release tablet products of pramipexole dihydrochloride under ANDA202353, covering five strengths and several labeling supplements.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
FDA ANDA202002: Strides Pharma Submits Original Application for IMIQUIMOD 5% Cream
Strides Pharma filed ANDA202002 for a 5% IMIQUIMOD topical cream (product 001). The original submission was listed as approved on 24‑Jun‑2014.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
FDA Approves ANDA201251 for Vancomycin Hydrochloride Injection
FDA approved ANDA201251 submitted by Teva Pharm USA for two vancomycin hydrochloride injectable products (500 mg and 1 g per vial), both listed as discontinued.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
FDA Records Submissions for Teva’s Discontinued Amlodipine/Valsartan/HCTZ Tablets (ANDA 200435)
FDA records multiple labeling submissions for Teva’s discontinued oral tablet combining amlodipine besylate, valsartan, and hydrochlorothiazide (ANDA 200435). All listed product variants are marked discontinued.
Actualizaciones regulatorias
16 sept 2026•1 min de lectura
Medtronic Identifies Reflective Material Variation in Sterile Passive Spheres
Health Canada reports a limited number of Medtronic sterile passive spheres have variable reflective coating that could affect navigation system tracking.